{"status": "OK", "response": {"docs": [{"type_of_material": "Op-Ed", "blog": [], "news_desk": "OpEd", "lead_paragraph": "Companies spend billions of dollars on drug testing each year. And yet for a surprising number of medicines, we still don\u2019t know if they\u2019re safe or effective.", "headline": {"main": "Do Clinical Trials Work?", "kicker": "Opinion", "print_headline": "Do Clinical Trials Work?", "content_kicker": "Opinion"}, "abstract": "Op-Ed article by author Clifton Leaf highlights fact that doctors have no idea why or whether anti-cancer drug Avastin works, even after 16 years of clinical trials involving tens of thousands of patients; notes that this is the norm for clinical testing of experimental medicines and calls for a smarter system for evaluating drugs.", "print_page": "1", "word_count": "2017", "_id": "51e19c397988102a01491c2e", "snippet": "Companies spend billions of dollars on drug testing each year. And yet for a surprising number of medicines, we still don\u2019t know if they\u2019re safe or effective.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/07/14/opinion/sunday/do-clinical-trials-work.html", "multimedia": [{"subtype": "wide", "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbWide-v2.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbWide-v2.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-articleLarge.jpg", "height": 628, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-articleLarge.jpg", "xlargeheight": "628"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbStandard-v2.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": "Sunday Review", "keywords": [{"value": "Clinical Trials", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Cancer", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Avastin (Drug)", "is_major": "Y", "rank": "4", "name": "subject"}, {"value": "Genentech Inc", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Genetics and Heredity", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Gilbert, Mark R", "is_major": "N", "rank": "7", "name": "persons"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Clifton", "lastname": "LEAF"}], "original": "By CLIFTON LEAF"}, "document_type": "article", "pub_date": "2013-07-14T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": null, "headline": {"main": "Potential for Deals Drives a Big Surge in the Biotech Sector ", "kicker": "DealBook", "print_headline": "Potential for Deals Drives a Big Surge in the Biotech Sector"}, "abstract": "The rise of personalized medicine has spurred giant pharmaceutical companies to home in on small biotechnology firms.", "print_page": null, "word_count": "1344", "_id": "51df366b7988102a01491750", "snippet": "The rise of personalized medicine has spurred giant pharmaceutical companies to home in on small biotechnology firms.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://dealbook.nytimes.com/2013/07/11/biotech-companies-surge-as-investors-flock-to-them/", "multimedia": [{"subtype": "wide", "url": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-articleLarge.jpg", "height": 400, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-articleLarge.jpg", "xlargeheight": "400"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-thumbStandard-v2.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/07/12/business/dbpix-biotech/dbpix-biotech-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": "Dealbook", "keywords": [{"value": "Biotechnology", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2", "name": "subject"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Arlene", "lastname": "WEINTRAUB"}], "original": "By ARLENE WEINTRAUB"}, "document_type": "blogpost", "pub_date": "2013-07-11T18:42:13Z", "section_name": "Business Day"}], "meta": {"hits": 2, "offset": 0, "time": 27}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}